REVIEW article
Front. Cell Dev. Biol.
Sec. Cancer Cell Biology
This article is part of the Research TopicEpigenetic Regulation in Cancer: Mechanisms, Implications, and Therapeutic InterventionsView all 10 articles
H19 and IGF2 Imprinting from Embryogenesis to Oncogenesis
Provisionally accepted
- Georgetown University Medical Center, Washington D.C., United States
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
The imprinted H19/IGF2 locus is critical for fetal development and, when dysregulated, contributes to tumorigenesis. This review examines the mechanisms regulating imprinting through DNA methyltransferases, alongside shared signaling pathways, such as PI3K/AKT, that operate across both embryonic development and tumorigenesis. Parent-of-origin methylation at this locus coordinates differential gene activity: IGF2 promotes organogenesis and placental angiogenesis through mitogenic signaling, while H19, a long non-coding RNA that serves as a precursor for miR-675-5p, prevents fetal overgrowth, regulates trophoblast invasion, and modulates epithelial-to-mesenchymal transitions (EMT). Loss of imprinting (LOI) at this locus disrupts normal gene expression, contributing to the development of cancer and imprinting disorders. Overexpression of H19 activates the PI3K/AKT pathway and silences tumor suppressor genes such as let-7b through sponging target genes and subsequently inducing EMT. While LOI of IGF2 leads to cancer through upregulation of the Wnt3 pathway. H19 and IGF2 play opposing yet coordinated roles in embryogenesis, with IGF2 promoting proliferation and H19 restricting overgrowth, a balance essential for proper tissue development. When epigenetically disrupted, it enables tumors to reactivate developmental pathways that drive unchecked growth, EMT, metastasis, and resistance to apoptosis. Controlling the balance of imprinting of the H19/IGF2 locus presents a promising mechanism for future therapies.
Keywords: Cancer Epigenetics, DNA Methylation, Embryonic Development, Epigenetic regulation, Genomic Imprinting, H19/IGF2 locus, Loss of imprinting (LOI), noncoding RNA
Received: 03 Sep 2025; Accepted: 06 Feb 2026.
Copyright: © 2026 Ortega*, Saeed*, White*, Tajanlangit* and Gallicano. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: G. Ian Gallicano
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.